NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.35 -0.25 (-3.29 %) (As of 01/27/2020 09:42 AM ET) Add Compare Today's Range$7.13Now: $7.35▼$7.4550-Day Range$3.21MA: $4.90▼$8.8352-Week Range$2.30Now: $7.35▼$13.90Volume40,729 shsAverage Volume1.36 million shsMarket Capitalization$199.59 millionP/E RatioN/ADividend YieldN/ABeta2.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LJPC Previous Symbol CUSIPN/A CIK920465 Webhttp://www.lajollapharmaceutical.com/ Phone858-207-4264Debt Debt-to-Equity RatioN/A Current Ratio5.01 Quick Ratio4.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.06 million Price / Sales19.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book6.56Profitability EPS (Most Recent Fiscal Year)($7.85) Net Income$-199,470,000.00 Net Margins-683.88% Return on Equity-715.11% Return on Assets-76.89%Miscellaneous Employees169 Outstanding Shares27,160,000Market Cap$199.59 million Next Earnings Date3/2/2020 (Estimated) OptionableOptionable Receive LJPC News and Ratings via Email Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LJPC Rates by TradingView La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions What is La Jolla Pharmaceutical's stock symbol? La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC." How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.03. The biopharmaceutical company earned $5.71 million during the quarter, compared to analysts' expectations of $6.96 million. La Jolla Pharmaceutical had a negative net margin of 683.88% and a negative return on equity of 715.11%. View La Jolla Pharmaceutical's Earnings History. When is La Jolla Pharmaceutical's next earnings date? La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for La Jolla Pharmaceutical. What price target have analysts set for LJPC? 4 brokers have issued twelve-month target prices for La Jolla Pharmaceutical's stock. Their forecasts range from $19.00 to $20.00. On average, they expect La Jolla Pharmaceutical's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 165.4% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical. What is the consensus analysts' recommendation for La Jolla Pharmaceutical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical. What are Wall Street analysts saying about La Jolla Pharmaceutical stock? Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock: 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (8/8/2019) 2. HC Wainwright analysts commented, "We base our $26 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $1.69/share to arrive at our price target. We value the current commercial business at $8.76 per share and the pipeline at $15.68 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.51, discounted at 15%." (4/24/2019) Has La Jolla Pharmaceutical been receiving favorable news coverage? News headlines about LJPC stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for La Jolla Pharmaceutical. Are investors shorting La Jolla Pharmaceutical? La Jolla Pharmaceutical saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,660,000 shares, a drop of 8.3% from the December 31st total of 3,990,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is presently 3.4 days. Approximately 15.3% of the company's shares are short sold. View La Jolla Pharmaceutical's Current Options Chain. Who are some of La Jolla Pharmaceutical's key competitors? Some companies that are related to La Jolla Pharmaceutical include AVITA MED LTD/S (RCEL), Vericel (VCEL), Proteon Therapeutics (PRTO), Adverum Biotechnologies (ADVM), Atara Biotherapeutics (ATRA), Oyster Point Pharma (OYST), GENFIT S A/ADR (GNFT), Twist Bioscience (TWST), Cellectis (CLLS), MeiraGTx (MGTX), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Rubius Therapeutics (RUBY), Nantkwest (NK) and Avrobio (AVRO). What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), El Pollo LoCo (LOCO), Neurocrine Biosciences (NBIX), Sarepta Therapeutics (SRPT), Exelixis (EXEL), XOMA (XOMA), Juno Therapeutics (JUNO), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Who are La Jolla Pharmaceutical's key executives? La Jolla Pharmaceutical's management team includes the folowing people: Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)Mr. James M. Rolke, Chief Scientific Officer (Age 50)Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48) Who are La Jolla Pharmaceutical's major shareholders? La Jolla Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.05%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical. Which major investors are buying La Jolla Pharmaceutical stock? LJPC stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical. How do I buy shares of La Jolla Pharmaceutical? Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is La Jolla Pharmaceutical's stock price today? One share of LJPC stock can currently be purchased for approximately $7.35. How big of a company is La Jolla Pharmaceutical? La Jolla Pharmaceutical has a market capitalization of $199.59 million and generates $10.06 million in revenue each year. The biopharmaceutical company earns $-199,470,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.View Additional Information About La Jolla Pharmaceutical. What is La Jolla Pharmaceutical's official website? The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com/. How can I contact La Jolla Pharmaceutical? La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected] MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 337 (Vote Outperform)Underperform Votes: 305 (Vote Underperform)Total Votes: 642MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index?
